Exact Sciences provided preliminary guidance for its fourth quarter performance as per which, the company expects to exceed consensus revenue estimates. In an …
EXACT Sciences Corporation (NASDAQ:EXAS) announced that it expects to end the second quarter of 2015 with approximately 21,000 completed Cologuard tests. More than 13,800 …
EXACT Sciences Corporation (NASDAQ:EXAS) and The University of Texas MD Anderson Cancer Center announced an agreement to jointly develop and commercialize blood-based screening and …
Exact Sciences Corporation (NASDAQ:EXAS) announced that, in support of the Company’s continued growth plans, it issued restricted stock units covering a total of …
EXACT Sciences Corporation (NASDAQ:EXAS) announced expanded patient access to Cologuard as a result of several insurers now covering the test. Cologuard is now covered …
Exact Sciences Corp. (NASDAQ:EXAS) announced Wheaton Franciscan Healthcare is the first healthcare system in Milwaukee to offer Cologuard®, the first and onlyFDA-approved noninvasive stool …
Exact Sciences Corp. (NASDAQ:EXAS) announced that Aetna, one of the country’s leading health plans, will cover Cologuard under its Medicare Advantage plan, reaching 967,000 …
Exact Sciences Corp. (Nasdaq:EXAS) announced its financial results for the quarter and year ended Dec.
(BUSINESS WIRE)– Exact Sciences Corp. (NASDAQ:EXAS) today announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard®, the first and …
(BUSINESS WIRE)– Exact Sciences Corp. (Nasdaq:EXAS) today announced that during 2014 it completed and reported a diagnostic result for 4,024 Cologuard tests, more …
